Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy

BackgroundImmune checkpoint inhibitor (ICI)-based combination therapy has opened a new avenue for the treatment of multiple malignancies including hepatocellular carcinoma (HCC). However, considering the unsatisfactory efficacy, biomarkers are urgently needed to identify the patients most likely to...

Full description

Bibliographic Details
Main Authors:	De-Zhen Guo, Shi-Yu Zhang, San-Yuan Dong, Jia-Yan Yan, Yu-Peng Wang, Ya Cao, Sheng-Xiang Rao, Jia Fan, Xin-Rong Yang, Ao Huang, Jian Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Oncology
Subjects:	hepatocellular carcinoma prognostic models immunotherapy lenvatinib circulating immune index
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1109742/full

Similar Items

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
by: De-Zhen Guo, et al.
Published: (2023-02-01)

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine
by: Yang Gao, et al.
Published: (2021-07-01)

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS
by: Jun Guo, et al.
Published: (2021-10-01)

Effectiveness and safety of transarterial chemoembolization combined with PD-1 inhibitors and lenvatinib for unresectable intrahepatic cholangiocarcinoma
by: Jin-Tao Huang, et al.
Published: (2025-02-01)

Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro
by: Xinyue Wang, et al.
Published: (2023-01-01)

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
by: Yong Yi, et al.
Published: (2022-11-01)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021-03-01)

Opportunities and challenges of liquid biopsy in liver cancer
by: Yu-Chen Zhong, et al.
Published: (2023-12-01)

Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
by: Yasutoshi Fujii, et al.
Published: (2021-06-01)

Integration of Inflammation-Immune Factors to Build Prognostic Model Predictive of Prognosis and Minimal Residual Disease for Hepatocellular Carcinoma
by: Xin Xu, et al.
Published: (2022-06-01)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
by: Cong-Cong Wang, et al.
Published: (2023-06-01)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023-09-01)

Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression
by: Peng Sun, et al.
Published: (2024-07-01)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis
by: Guangwei Yan, et al.
Published: (2024-08-01)

Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
by: Ming‐Hao Xu, et al.
Published: (2023-04-01)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
by: Jia Luo, et al.
Published: (2022-12-01)

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
by: Tao M, et al.
Published: (2023-07-01)

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
by: Jia M, et al.
Published: (2022-09-01)

Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma
by: Jieying Yang, et al.
Published: (2023-07-01)

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
by: Yun Zhu, et al.
Published: (2021-09-01)

Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib
by: Bo Liu, et al.
Published: (2022-02-01)

Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis
by: Yue Chen, et al.
Published: (2024-08-01)

Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts
by: De-Zhen Guo, et al.
Published: (2024-08-01)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
by: Jie Mei, et al.
Published: (2021-02-01)

Lenvatinib resistance mechanism and potential ways to conquer
by: Wentao Bo, et al.
Published: (2023-04-01)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
by: Jia-Xin Huang, et al.
Published: (2023-08-01)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
by: Tetsu Tomonari, et al.
Published: (2021-11-01)

Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma
by: Zhou C, et al.
Published: (2023-04-01)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
by: Wenzhe Fan, et al.
Published: (2023-01-01)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
by: He-nan Qin, et al.
Published: (2022-11-01)

Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
by: Juan Wu, et al.
Published: (2023-10-01)

Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study
by: Jian Huang, et al.
Published: (2023-07-01)

Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti–PD–1 antibody
by: Bin Xu, et al.
Published: (2022-11-01)

RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2
by: Yarong Guo, et al.
Published: (2024-02-01)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
by: Clarissa Lam, et al.
Published: (2023-10-01)

Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
by: Nan-Qing Liao, et al.
Published: (2024-12-01)

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
by: Yusuke Kawamura, et al.
Published: (2020-10-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization
by: Shi Q, et al.
Published: (2023-10-01)